Julien Villeneuve, Sébastien Lepreux, Audrey Mulot, Annie M. Bérard, Arisa Higa‐Nishiyama, Pierre Costet, Victor De Ledinghen, Paulette Bioulac‐Sage, Charles Balabaud, Alan T. Nurden, Jean Rosenbaum, Eric Chevet, Jean Ripoche – 25 August 2010 – Inflammation and lipid metabolism pathways are linked, and deregulation of this interface may be critical in hepatic steatosis. The importance of the dialog between inflammatory signaling pathways and the unfolded protein response (UPR) in metabolism has been underlined.

Maureen M. Jonas, Joan M. Block, Barbara A. Haber, Saul J. Karpen, W. Thomas London, Karen F. Murray, Michael R. Narkewicz, Philip Rosenthal, Kathleen B. Schwarz, Brian J. McMahon – 25 August 2010 – Chronic hepatitis B virus (HBV) infection in children presents a therapeutic challenge for the practitioner. Decisions regarding selection of patients who may benefit from treatment, appropriate timing of treatment, and the choice of antiviral therapy are complex and are compounded by the limited number of drugs that have been studied in children.

23 August 2010

Gerald U. Denk, Silvia Maitz, Ralf Wimmer, Christian Rust, Pietro Invernizzi, Sacha Ferdinandusse, Wim Kulik, Andrea Fuchsbichler, Peter Fickert, Michael Trauner, Alan F. Hofmann, Ulrich Beuers – 20 August 2010 – NorUDCA (24‐norursodeoxycholic acid), the C23‐homolog of ursodeoxycholic acid (UDCA), showed remarkable therapeutic effects in cholestatic Mdr2 (Abcb4) (multidrug resistance protein 2/ATP‐binding cassette b4) knockout mice with sclerosing/fibrosing cholangitis.

Lieve Braeye, Ruben Vanheste – 20 August 2010

Marcos Martínez‐Clemente, Natàlia Ferré, Esther Titos, Raquel Horrillo, Ana González‐Périz, Eva Morán‐Salvador, Cristina López‐Vicario, Rosa Miquel, Vicente Arroyo, Colin D. Funk, Joan Clària – 20 August 2010 – We have shown that Alox15, the gene encoding for 12/15‐lipoxygenase (12/15‐LO), is markedly up‐regulated in livers from apolipoprotein E‐deficient (ApoE−/−) mice, which spontaneously develop nonalcoholic fatty liver disease secondary to hyperlipidemia.

Laura Llacuna, Cristina Bárcena, Lola Bellido‐Martín, Laura Fernández, Milica Stefanovic, Montserrat Marí, Carmen García‐Ruiz, José C. Fernández‐Checa, Pablo García de Frutos, Albert Morales – 20 August 2010 – Growth arrest–specific gene 6 (GAS6) promotes growth and cell survival during tissue repair and development in different organs, including the liver. However, the specific role of GAS6 in liver ischemia/reperfusion (I/R) injury has not been previously addressed. Here we report an early increase in serum GAS6 levels after I/R exposure.

Emanuele Nicastro, Giusy Ranucci, Pietro Vajro, Angela Vegnente, Raffaele Iorio – 20 August 2010 – The diagnosis of Wilson disease (WD) is challenging, especially in children. Early detection is desirable in order to avoid dramatic disease progression. The aim of our study was to re‐evaluate in WD children with mild liver disease the conventional diagnostic criteria and the WD scoring system proposed by an international consensus in 2001.

Pablo Bellot, Juan Carlos García‐Pagán, Rubén Francés, Juan G. Abraldes, Miguel Navasa, Miguel Pérez‐Mateo, José Such, Jaime Bosch – 20 August 2010 – Presence of bacterial DNA in noninfected patients with cirrhosis and ascites is associated with a marked inflammatory response including activation of the inducible form of nitric oxide synthase and release of nitric oxide, similar to that observed in patients with spontaneous bacterial peritonitis. Although presence of bacterial DNA is associated with an impaired prognosis, no information is available regarding its hemodynamic consequences.

Thomas J. Urban, Alexander J. Thompson, Shelton S. Bradrick, Jacques Fellay, Detlef Schuppan, Kenneth D. Cronin, Linda Hong, Alexander McKenzie, Keyur Patel, Kevin V. Shianna, John G. McHutchison, David B. Goldstein, Nezam Afdhal – 20 August 2010 – Genetic variation in the IL28B (interleukin 28B; interferon lambda 3) region has been associated with sustained virological response (SVR) rates in patients with chronic hepatitis C (CHC) who were treated with peginterferon‐α and ribavirin.